Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched a $1.0 billion offering of new senior secured notes due 2027. The company also plans to refinance its existing credit agreement, which includes approximately $2.5 billion in new term B loans and a $975 million revolving credit facility. Proceeds will fund the redemption of outstanding 6.125% and 9.000% senior notes due 2025 and related expenses. The redemption is conditional upon completing the refinancing and receiving at least $7.0 billion from related transactions. The offering is not registered under U.S. securities laws.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that Dr. Yehia Hashad will join Bausch + Lomb as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective January 31, 2022. Dr. Hashad brings over 25 years of experience in the pharmaceutical industry, with significant expertise in ophthalmic pharmaceuticals from Allergan/AbbVie and Novartis. His appointment aims to enhance the R&D capabilities at Bausch + Lomb, a leader in eye health products and services, as the company continues to innovate and build on its 170-year legacy.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to refinance its existing credit agreement, involving $2.5 billion in Term B loans and a $975 million revolving credit facility. The refinancing is contingent upon the initial public offering (IPO) of Bausch + Lomb, expected to enable Bausch Health to designate Bausch + Lomb as an unrestricted subsidiary. Additionally, the company plans to issue $1 billion in secured debt securities to facilitate the redemption of existing notes. The transactions are subject to market conditions and are expected to close in Q1 2022.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a significant step towards separating its eye health business by filing a Registration Statement on Form S-1 for a proposed IPO of its subsidiary, Bausch + Lomb. The IPO aims to sell common shares in both the U.S. and Canada, with specifics on share quantity and pricing yet to be determined. Major financial institutions like Morgan Stanley and Goldman Sachs are leading the offering, with market conditions influencing the timing and structure of the transaction. There are no assurances regarding the IPO's completion.

Bausch Health Companies (NYSE/TSX: BHC) will present a business and strategic update during a fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. CEO Joseph C. Papa expressed enthusiasm regarding the progress in unlocking company value, highlighting that preparations for the IPOs of Bausch + Lomb and Solta are nearly complete, pending market and regulatory conditions. The presentation will be available on their Investor Relations page.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that CEO Joseph C. Papa will speak at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. A live webcast of the event will be available on the company's Investor Relations page. Bausch Health is committed to improving lives through a range of healthcare products, focusing on eye health, gastroenterology, and dermatology.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the publication of a post-hoc analysis in The Journal of Emergency Medicine supporting RELISTOR (methylnaltrexone bromide) injection for treating opioid-induced constipation in severely ill patients with insufficient laxative response. The study revealed a significant increase in rescue-free laxation rates: 61.4% within 4 hours compared to 16% for placebo. Notably, RELISTOR did not compromise opioid pain relief, although gastrointestinal side effects were reported. This reinforces RELISTOR's therapeutic value, particularly in emergency settings.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its dermatology product, JUBLIA^® (efinaconazole) Topical Solution, has received the American Podiatric Medical Association (APMA) Seal of Approval. This recognition signifies the product's safety and efficacy in treating onychomycosis, a common fungal infection affecting toenails. JUBLIA^® has been available since 2014 for adults and was approved for children in 2020. The APMA's endorsement comes after a rigorous scientific review process, enhancing JUBLIA's credibility in the market.